| Bioactivity | JSH-009 is a novel, highly selective CDK9 inhibitor critical for regulating transcription elongation. JSH-009 demonstrated significant in vitro and in vivo efficacy against acute myeloid leukemia (AML)[1]. |
| CAS | 2247481-08-7 |
| Formula | C25H35ClN6O2S |
| Molar Mass | 519.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang L, et al. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Invest New Drugs. 2020 Oct;38(5):1272-1281. |
JSH-009
CAS: 2247481-08-7 F: C25H35ClN6O2S W: 519.10
JSH-009 is a novel, highly selective CDK9 inhibitor critical for regulating transcription elongation. JSH-009 demonstrat
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.